ArticleMovement disorders : official journal of the Movement Disorder Society2020
High γ-Aminobutyric Acid Content Within the Medial Prefrontal Cortex Is a Functional Signature of Somatic Symptoms Disorder in Patients With Parkinson's Disease.
Article in Movement disorders : official journal of the Movement Disorder Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Meta-analysis and open-source database for in vivo brain Magnetic Resonance spectroscopy in health and disease.Analytical biochemistry · 2023Pooled it
- GABAergic dysfunction in Parkinson's disease: insights from in vivo proton magnetic resonance spectroscopy.NPJ Parkinson's disease · 2026Article
- Neurotransmitter Dysregulation in Parkinson's Disease: Pathophysiological Insights and Therapeutic Perspectives.ACS chemical neuroscience · 2026Review
- Association between anxiety disorder, anxiolytic drugs, and risk of incident Parkinson's disease.NPJ Parkinson's disease · 2025Article
- The altered resting-state functional connectivity of thalamic subregions in patients with globus pharyngeus.Brain imaging and behavior · 2025Article
- Evaluating the Therapeutic Efficacy of rTMS Combined with Low-Dose Antipsychotic Medication in Somatic Symptom Disorder.Neuropsychiatric disease and treatment · 2025Article
- Psychiatric Disorders and Cognitive Fluctuations in Parkinson's Disease: Changing Approaches in the First Decades of the 21st Century.Brain sciences · 2024Review
- Meta-analysis and Open-source Database for In Vivo Brain Magnetic Resonance Spectroscopy in Health and Disease.bioRxiv : the preprint server for biology · 2023Article
- Impact of gradient scheme and non-linear shimming on out-of-voxel echo artifacts in edited MRS.NMR in biomedicine · 2023Article
- Scoping review update on somatic symptom disorder that includes additional Chinese data.General psychiatry · 2023Article
- Functional Neurologic Disorders, disorders to be managed by neurologists, or are neurologists wandering in a dangerous field with inadequate resources?Frontiers in psychiatry · 2023Review
- Molecular Imaging of the GABAergic System in Parkinson's Disease and Atypical Parkinsonisms.Current neurology and neuroscience reports · 2022Review
- Altered Medial Prefrontal Connectivity in Parkinson's Disease Patients with Somatic Symptoms.Movement disorders : official journal of the Movement Disorder Society · 2022Article
- Altered Brain Activity in Depression of Parkinson's Disease: A Meta-Analysis and Validation Study.Frontiers in aging neuroscience · 2022Article
- Upper brainstem GABA levels in Parkinson's disease.Magma (New York, N.Y.) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundThe dysfunctional activity of the medial prefrontal cortex has been associated with the appearance of the somatic symptom disorder, a key feature of the Parkinson's disease (PD) psychosis complex.
objectivesThe objectives of this study were to investigate whether the basal contents of inhibitory γ-aminobutyric acid and excitatory glutamate plus glutamine neurotransmitter levels are changed in the medial prefrontal cortex of patients with PD with somatic symptom disorder and whether this alteration represents a marker of susceptibility of PD to somatic symptom disorder, thus representing a signature of psychosis complex of PD.
methodsLevels of the γ-aminobutyric acid and glutamate plus glutamine were investigated, at rest, with proton magnetic resonance spectroscopy. Total creatine was used as an internal reference. The study cohort included 23 patients with somatic symptom disorder plus PD, 19 patients with PD without somatic symptom disorder, 19 healthy control subjects, and 14 individuals with somatic symptom disorder who did not show other psychiatric or neurological disorders.
resultsWe found that, compared with patients with PD without somatic symptom disorder or healthy control individuals, patients with somatic symptom disorder, with or without PD, show increased γ-aminobutyric acid/total creatine levels in the medial prefrontal cortex. The medial prefrontal cortex contents of glutamate plus glutamine/total creatine levels or γ-aminobutyric acid/glutamate plus glutamine were not different among groups.
conclusionsOur findings highlight a crucial pathophysiologic role played by high γ-aminobutyric acid within the medial prefrontal cortex in the production of somatic symptom disorder. This phenomenon represents a signature of psychosis complex in patients with PD. © 2020 International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.